Methylation changes and INS-IGF2 expression predict progression in early-stage Wilms tumor

Area of Science:

• Pediatric Oncology
• Epigenetics
• Cancer Genomics

Background:

• Wilms tumor is the most common pediatric kidney cancer, with high survival rates but a significant relapse risk (15%).
• Epigenetic alterations, specifically DNA methylation, are implicated in Wilms tumor development.
• Early identification of relapse risk is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the prognostic value of DNA methylation in identifying early relapse in stage I and II Wilms tumor patients with favorable histology.
• To identify potential DNA methylation biomarkers for monitoring disease progression.

Main Methods:

• Genome-wide DNA methylation analysis using microarrays on tumor tissues from relapsed and remission patients.
• Analysis of differentially methylated positions and regions, ROC analysis, and survival analysis.
• Gene expression analysis of IGF2 and INS-IGF2 using real-time PCR.

Main Results:

• Hypomethylation in intergenic regions was observed in patients with complete remission.
• Fourteen differentially methylated positions were identified as potential early relapse biomarkers.
• Increased INS-IGF2 gene expression correlated with disease relapse, suggesting a role in progression.

Conclusions:

• DNA methylation patterns hold prognostic potential for Wilms tumor, particularly for early relapse detection.
• INS-IGF2 expression may serve as a biomarker for disease progression.
• These findings support the development of methylation-based markers for personalized Wilms tumor management.